Omvoh® is now indicated for both major forms of Inflammatory Bowel Disease (IBD) – ulcerative colitis (UC) and Crohn’s ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Innovent Biologics, the first Chinese firm to gain approval for a GLP-1 weight loss and diabetes drug, has partnered with JD ...

AMGN has a strong balance sheet with a BBB+ credit rating from S&P. This is supported by $8.8 billion in cash on hand and a ...

Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Netflix, Inc ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

If you wish to turn $10,000 into $50,000 by 2035, you’re looking at a 400% gain over a 10-year horizon. In the past decade, ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

A phenotype-based profiling test can help predict whether a patient might respond better to one antiobesity medicine or ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...